selected publications
-
Journal Article
- Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes 2017
- Insulin dose and cardiovascular mortality in the ACCORD Trial. Diabetes care. 2015
- Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. Diabetologia. 2014
- Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes care. 2014
- Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International. 2012
- Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes care. 2012
- Long-term effects of intensive glucose lowering on cardiovascular outcomes. New England Journal of Medicine. 2011
- Near-Normalization of Glucose and Microvascular Diabetes Complications: Data from ACCORD and ADVANCE. Therapeutic Advances in Endocrinology and Metabolism. 2011
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (London, England). 2010
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (London, England). 2010
- Effects of combination lipid therapy in type 2 diabetes mellitus. New England Journal of Medicine. 2010
- Effects of intensive blood-pressure control in type 2 diabetes mellitus. New England Journal of Medicine. 2010
- The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ (Clinical research ed.). 2010
- Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine. 2008